Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | PKM | P14618 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | XDH | P47989 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 2/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.43 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL453506 | 0.82 | KDM4E (0.48) | MAPTHPGDALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL412348 | 0.77 | MEN1 (0.43) | MAPTKMT2AMEN1MAPK1PKM | |
| SCHEMBL20915705 | 0.76 | XDH (0.49) | MAPTKMT2AMEN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL413396 | 0.76 | PTGS2 (0.49) | MAPTKMT2AMEN1HTTNPSR1 | |
| SCHEMBL28116018 | 0.76 | TDP1 (0.50) | MAPTHPGDKMT2AMEN1ALDH1A1 | |
| SCHEMBL28018782 | 0.76 | KMT2A (0.50) | MAPTHPGDKMT2AMEN1ALDH1A1 | |
| SCHEMBL22353121 | 0.76 | RAB9A (0.49) | MAPTHPGDKMT2AMEN1ALDH1A1 | |
| SCHEMBL28270530 | 0.76 | MAPK13 (0.54) | MAPTHPGDALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL1260158 | 0.76 | MAPT (0.45) | MAPTHPGDKMT2AMEN1ALDH1A1 | |
| SCHEMBL28264084 | 0.76 | TDP1 (0.50) | MAPTHPGDKMT2AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220024900-A1 | Compounds and Their Use for Reducing Uric Acid Levels | ACQUIST LLC (US) | 2022-01-27 | — | — | US | disclosed |
| US-11168075-B2 | Compounds and their use for reducing uric acid levels | ACQUIST LLC (US) | 2021-11-09 | — | — | US | disclosed |
| US-20200347034-A1 | Compounds and Their Use for Reducing Uric Acid Levels | ACQUIST LLC (US) | 2020-11-05 | — | — | US | disclosed |
| US-10759784-B2 | Compounds and their use for reducing uric acid levels | ACQUIST LLC (US) | 2020-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200347034-A1 | Compounds and Their Use for Reducing Uric Acid Levels | XDH, OAT, PON1 | MAPT 3322/4885HPGD 455/4885KMT2A 3084/4885 |
| US-20220024900-A1 | Compounds and Their Use for Reducing Uric Acid Levels | XDH, OAT, PON1 | MAPT 3322/4885HPGD 455/4885KMT2A 3084/4885 |
| US-11168075-B2 | Compounds and their use for reducing uric acid levels | XDH, OAT, PON1 | MAPT 3322/4885HPGD 455/4885KMT2A 3084/4885 |
| US-10759784-B2 | Compounds and their use for reducing uric acid levels | XDH, OAT, PON1 | MAPT 3322/4885HPGD 455/4885KMT2A 3084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.